Immunology, Internal medicine, Minimal residual disease, Acute lymphocytic leukemia and Leukemia are his primary areas of study. The Immunology study combines topics in areas such as Interleukin 12 and Cancer research. His study in Internal medicine is interdisciplinary in nature, drawing from both Immunophenotyping, Oncology and Pediatrics.
Dario Campana combines subjects such as Neoplasm, Flow cytometry and Cumulative incidence with his study of Minimal residual disease. Dario Campana has included themes like Chemotherapy, Gastroenterology, Childhood Acute Lymphoblastic Leukemia, Philadelphia chromosome and Bone marrow in his Acute lymphocytic leukemia study. His studies in Leukemia integrate themes in fields like Molecular biology, Haematopoiesis and Myeloid leukemia.
His scientific interests lie mostly in Immunology, Minimal residual disease, Internal medicine, Leukemia and Cancer research. As part of the same scientific family, Dario Campana usually focuses on Immunology, concentrating on Interleukin 12 and intersecting with Natural killer cell. His Minimal residual disease research is multidisciplinary, relying on both Childhood Acute Lymphoblastic Leukemia, Myeloid leukemia, Flow cytometry and Polymerase chain reaction.
His studies deal with areas such as Gastroenterology and Oncology as well as Internal medicine. His work deals with themes such as Myeloid, Hematology, Hematopoietic stem cell transplantation and Haematopoiesis, which intersect with Leukemia. His work carried out in the field of Cancer research brings together such families of science as Cell, Cell therapy, Receptor, Cytotoxicity and Immunotherapy.
Dario Campana mainly investigates Minimal residual disease, Cancer research, Internal medicine, Oncology and Immunology. Dario Campana interconnects Body mass index, Clinical trial, Pediatrics and Clinical significance in the investigation of issues within Minimal residual disease. The Cancer research study combines topics in areas such as Cancer, Immunotherapy, Cell, T cell and Antibody-dependent cell-mediated cytotoxicity.
Internal medicine is closely attributed to Gastroenterology in his work. His research in Oncology intersects with topics in Down syndrome, Hematopoietic stem cell transplantation, Myeloid leukemia and Lymphoblastic Leukemia. Dario Campana focuses mostly in the field of Immunology, narrowing it down to matters related to NKG2D and, in some cases, Interleukin 12, Natural killer cell and CD3.
Dario Campana mostly deals with Minimal residual disease, Immunology, Pediatrics, Immunotherapy and Cancer research. His Minimal residual disease study necessitates a more in-depth grasp of Internal medicine. His study ties his expertise on Interleukin 12 together with the subject of Immunology.
The various areas that Dario Campana examines in his Pediatrics study include Childhood Acute Lymphoblastic Leukemia, Clinical trial and Remission induction. His Immunotherapy research integrates issues from Receptor and Antigen. His study in Cancer research is interdisciplinary in nature, drawing from both Cell, Antibody and T cell.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.
Eng Juh Yeoh;Mary E. Ross;Sheila A. Shurtleff;W. Kent Williams.
Cancer Cell (2002)
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Jinghui Zhang;Li Ding;Linda Holmfeldt;Gang Wu.
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.
Charles G Mullighan;Xiaoping Su;Jinghui Zhang;Ina Radtke.
The New England Journal of Medicine (2009)
Treating childhood acute lymphoblastic leukemia without cranial irradiation.
Ching Hon Pui;Dario Campana;Deqing Pei;W. Paul Bowman.
The New England Journal of Medicine (2009)
Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
Michael C. Milone;Jonathan D. Fish;Jonathan D. Fish;Carmine Carpenito;Richard G. Carroll.
Molecular Therapy (2009)
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia
Elaine Coustan-Smith;Charles G. Mullighan;Mihaela Onciu;Frederick G. Behm.
Lancet Oncology (2009)
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells
Chihaya Imai;Shotaro Iwamoto;Shotaro Iwamoto;Dario Campana;Dario Campana.
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia
C. Imai;K. Mihara;M. Andreansky;I. C. Nicholson.
Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy
Hiroyuki Fujisaki;Harumi Kakuda;Noriko Shimasaki;Chihaya Imai.
Cancer Research (2009)
Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia.
Elaine Coustan-Smith;Jose Sancho;Michael L. Hancock;James M. Boyett.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: